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INTRODUCTION           
Hepatitis B virus (HBV), hepatitis C virus (HCV) 
and human immune deﬁciencyvirus(HIV)infections
are among the most important world public health 
problems representing a signiﬁcant cause of
morbidity and mortality, especially in developing 
countries. It is estimated that 350 million people 
worldwide (7%) are chronic HBV carriers[1,2] and 
600,000 die each year from HBV-related liver disease 
or hepatocellular carcinoma[3,4]. HCV infection is 
found in approximately 160 million people (3%) out 
of the world population and is the most common 
chronic blood borne infection in the world[5-7]. In 
addition, prevalence of human immunodeﬁciency
virus (HIV) is increasing everyday and it has become 
a disaster for humankind in some areas[4]. 
Their transmission occurs, mainly, through 
direct contact with blood, intravenous injections, 
transfusion, and sexual relations[8]. Over many 
years, hepatitis was the main cause of transfusion-
associated chronic disease, liver cirrhosis, 
hepatocellular carcinoma, and death[9]. Both HCV 
and HBV infections are also of major public health 
concern and the prevention of these two viral 
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increase in the overall prevalence of HBsAg and HBcAb 
(from 0.015% to 0.02%) and the prevalence of HCVAb 
(from 0.06% to 0.48%) during the study period (p < 0.05). 
Three male donors were co-infected by HCV and HBV.
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diseases is important. The infected individuals are 
at risk of chronic liver disease (5 to 10% of HBV 
and more than 50% of HCV)[10]. HIV infection is 
one of the most important public health concerns. 
A number of risk factors such as needle sharing 
and drug injection have been identiﬁed for HIV
infection[11].
For more than a decade, the screening of blood 
donors for HBV and HCV and HIV infection became 
obligatory in Iran as part of the control program, 
leading to a tighter control of blood samples used 
in transfusion. However, few studies have been 
carried out with wide variation in the prevalence 
of these viruses among Iranian blood donors. The 
prevalence of HBsAg, anti-HCV, and anti-HIV was 
0.6, 1.1 and 0%, respectively in Kashan in 2000[12]. In 
Zahedan, the prevalence of HBsAg and anti-HCV 
was 5.19 and 1.9%, respectively[13]. Therefore, the 
aim of this study was to determine the prevalence of 
HBsAg, anti-HCV antibody and anti-HIV antibody 
in voluntary blood donors. This report presents the 
results of a retrospective study of screening blood 
donors in Char Mahal, a central province of Iran 
from 2004 to 2006. 
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MATERIAL AND METHODS
This is a retrospective and descriptive study in 
which data were obtained from the Laboratory of 
the Blood Transfusion Center (BTC) of Share-Kord, 
Iran. The study was approved by the local ethical 
committee. The data included the markers of HBV 
(HbsAg and HBcAb), antibodies against HIV and 
HCV obtained from 35,124 blood donor referred to 
the center during 2004-2006. These samples were 
analyzed using immuno-enzymatic tests (ELISA; 
Ortho, USA and Western blotting; Gene Labs 
Diagnostics, Ltd). All HIV and HCV positive samples 
were conﬁrmed by Western blotting. The HBsAg
positive samples were conﬁrmed by HBcAb.
RESULTS
Our results showed that out of 35,124 samples 
(blood donors), 38 (0.1%) were positive for HBsAg, 
26 (0.07%) for anti-HBc, 74 (0.2%) for HCV speciﬁc
antibody (conﬁrmed by Western blotting) and one
(0.002%) for anti-HIV antibody. The mean age of 
HBV and HCV infected individuals was 32.4 and 33.4 
years respectively. Two out of the 38 (5.2%) HBV and 
three out of the 74 (4%) HCV positives were female. 
There was no signiﬁcant relationship between HBV
and HCV infections and gender (p > 0.05). Three 
male donors were co-infected by HCV and HBV. 
Also, there was no signiﬁcant relationship between
HBV / HCV co-infection and gender (p > 0.05).
Based on the results, the overall prevalence of 
HBsAg, anti-HBc, and particularly anti-HCV was 
signiﬁcantly increased from 2004 to 2006. HBsAg and
anti-HBc prevalence increased signiﬁcantly from
0.015% in 2005 to 0.02% in 2006 (p < 0.05). Similarly, 
there was increase in anti-HCV prevalence among 
the blood donors from 0.06% in 2005 to 0.48% in 
2006 (p < 0.05).
DISCUSSION
We veriﬁed that the prevalence of HBsAg, anti-
HBc, anti-HCV and anti-HIV markers in Shahre-
kord, Iran increased signiﬁcantly from 2004 to 2006.
In this study, the overall 0.1% HBsAg prevalence in 
the volunteer blood donors was lower than that in 
some other Iranian cities like Kashan (0.6%)[12] and 
Zahedan[13]. However, a comparison with developed 
countries, like Germany (0.16% in 1997-2002)[14], 
United States (0.07% in 2002)[15], Italy (0.003% in 1994-
1997)[16], and Canada (0.012% in 2000)[17] showed that 
HBsAg prevalence in Shahre-Kord blood donors was 
higher.  The overall prevalence for anti-core antibody 
(HBc) in the Shahre-Kord specimens (0.07%) was 
lower than that in Urmiae (0.57% [18], Kashan (1.1%)[12], 
Markazi (0.2%)[19], Zahedan(1.9%)[13] but was higher 
than in Italy (0.03%)[16]. 
The overall prevalence for anti-HCV marker in 
blood donors in Share-Kord during this period was 
0.2%. This marker has been found to be variable 
in different regions of Iran, ranging from 1.9% 
in Zahedan[13] to 0.2% in the central province[19]. 
Although the HCV prevalence was not as high as 
in other cities in this country, it has increased since 
2005. These data should alert the regional ofﬁcials
to focus action on HCV prevention in view of the 
unavailability of a vaccine. 
As observed for the HBsAg and anti-HBcAb 
prevalence, the anti-HCV prevalence found in our 
region was higher than in developed countries like 
United States (0.25% in 2002)[20], Germany (0.1% in 
1997/2002)[14], Canada (0.017% in 2000)[17] and Italy 
(0.002% in 1994/1997)[16]. 
Another agent, which has similar transmission 
route as HBV, is HIV. There is a potential hazard 
for everybody in the world because of the 
characteristics of the diseases[4]. Although in this 
study, the prevalence of HIV was 0.002%, Iran is not 
a sensitive area because of few visitors from other 
countries and cultural circumstances. However, 
there are young populations including drug-users 
who are not well informed about the disease and are 
among the most important high risk groups. 
Comparing with other developed countries, 
HBV and HCV prevalence in Iran is high. This study 
also demonstrates that HCV infection is a serious 
problem in our region, which requires further 
study and greater attention on the part of federal 
government health authorities. 
CONCLUSION
This study suggests that it is necessary to 
investigate risk factors and risk groups for these 
infections in Iran. In the light of these results, an 
effective control and training program for civilians 
should be implemented.
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